Q32 Bio Inc.
QTTB· Nasdaq· Pharmaceutical Preparations
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- -62.4%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +81.9%
We record prices for the companies we cover; QTTB is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 12.3M
- Revenue
- $53.7M
- Free cash flow
- -$33.5M
- Owner earnings
- -$38.8M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- 31.5%
- Net
- 55.5%
- Free cash flow
- -62.4%
- Owner earnings
- -72.2%
- Stock pay
- 9.8%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- 71.0%
- ROE, 5 yr avg
- –
Growth (CAGR)
- Revenue, 3 yr
- 155.9%
- Revenue, 5 yr
- 81.9%
- Revenue, 8 yr
- –
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 8 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 8 yr
- –
Financial health · FY2025
- Cash and investments
- $48.3M
- Total debt
- –
- Net cash
- –
- Debt/Equity
- –
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- –
Financials: ten years from the 10-Ks
Revenue
$53.7M
+39.1% a year over 8 years
FY2017FY2025
Margins
Operating31.5%Net55.5%
FY2025
FY2017FY2025
Free cash flow and owner earnings
Free cash flow-$33.5MOwner earnings-$38.8M
FY2025
FY2017FY2025
Diluted shares
12.3M
+1659.8% over 8 years, net dilution
FY2017FY2025
Net cash
–
$78.0M more cash than debt
FY2017FY2025
Every figure, year by year
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| The business | |||||||||
| Revenue | – | $5.3M | $1.7M | $2.7M | $34.0M | $3.2M | $1.2M | $0 | $53.7M |
| Revenue growth | – | – | -68.7% | 62.2% | 1157.3% | -90.6% | -64.0% | -100.0% | – |
| Gross margin | – | – | – | – | – | – | – | – | – |
| Operating margin | – | -1126.0% | -6599.2% | -4821.0% | -282.4% | -4154.6% | -4174.3% | – | 31.5% |
| Net income | -$30.0M | -$55.6M | -$103.9M | -$128.7M | -$95.8M | -$5.0M | -$53.7M | -$47.7M | $29.8M |
| Net margin | – | -1044.3% | -6237.5% | -4762.9% | -281.9% | -156.0% | -4649.0% | – | 55.5% |
| Diluted EPS | – | – | – | – | $-136.67s | $-7.11s | $-153.96 | $-6.58 | $2.42 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – |
| Cash | |||||||||
| Operating cash flow | $6.5M | -$42.6M | -$91.4M | -$94.3M | -$109.8M | -$113.7M | -$18.7M | -$67.7M | -$33.5M |
| Capital expenditure | $2.0M | $24.9M | $21.8M | $3.7M | $2.4M | $1.3M | $5.0K | $75.0K | $0 |
| Free cash flow | $4.5M | -$67.5M | -$113.2M | -$98.1M | -$112.1M | -$114.9M | -$18.7M | -$67.8M | -$33.5M |
| Stock-based compensation | $277.0K | $2.6M | $7.6M | $13.2M | $17.2M | $13.1M | $1.4M | $4.4M | $5.3M |
| Owner earnings? | $4.2M | -$70.1M | -$120.8M | -$111.3M | -$129.4M | -$128.0M | -$20.1M | -$72.2M | -$38.8M |
| Free cash flow per share | – | – | – | – | $-160.26 | $-158.20 | $-53.52 | $-7.02 | $-2.72 |
| Capital allocation | |||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – | – | – |
| Diluted shares | – | – | – | – | 699,788.835s | 726,579.266s | 349,060 | 9.7M | 12.3M |
| Share count change? | – | – | – | – | – | 3.8% | -52.0% | 2666.8% | 27.5% |
| Balance sheet | |||||||||
| Cash and equivalents | $51.6M | $38.2M | $53.8M | $217.4M | $108.4M | $34.0M | $25.6M | $78.0M | $48.3M |
| Short-term investments | $78.1M | $176.5M | $208.6M | $0 | $47.5M | $141.0M | $0 | $0 | – |
| Total debt | – | – | – | – | – | $30.0M | $38.6M | $0 | – |
| Net debt | – | – | – | – | – | -$145.0M | $13.0M | -$78.0M | – |
| Shareholders' equity | -$39.5M | $196.4M | $258.5M | $196.0M | $169.7M | -$130.7M | -$182.9M | $5.7M | $42.0M |
Latest filings
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Earnings release |
| 2026-05-05 | 10-Q | Quarterly report |
| 2026-05-05 | 8-K | Earnings release |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-03-10 | 10-K | Annual report |
| 2026-03-10 | 8-K | Earnings release |
| 2025-11-13 | 10-Q | Quarterly report |
| 2025-11-13 | 8-K | Earnings release |
| 2025-08-06 | 10-Q | Quarterly report |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
